Durable transplant immune tolerance
Getting a recipient's immune system to accept a foreign or engineered organ indefinitely without lifelong immunosuppression.
State of the art
Gene-edited pig kidneys functioned in human recipients for up to 271 days before irreversible rejection (2025) while still requiring heavy immunosuppression; donor-cell-based tolerance protocols remain limited to small HLA-matched cohorts.
- Chronic antibody-mediated rejection proceeds even under current immunosuppression
- Tolerance protocols trade rejection risk for conditioning toxicity and graft-versus-host disease
- No assay predicts which recipients can be safely weaned off drugs
Who’s working on it
- Medeor TherapeuticsStartup
Its Phase 3 MDR-101 trial left 15 of 20 HLA-matched living-donor kidney recipients functionally tolerant and off all immunosuppression two years after withdrawal, with no graft loss or GVHD (Am J Transplant, 2025)
- Dixon KaufmanResearcherUniversity of Wisconsin-Madison
First author of the MDR-101 Phase 3 report (2025), the first randomised controlled demonstration of durable drug-free tolerance in kidney transplantation
- Megan SykesResearcherColumbia Center for Translational Immunology
Pioneered minimal-conditioning mixed chimerism and xenogeneic thymic transplantation for tolerance; awarded the 2025 Starzl Prize for the path to xenograft tolerance
- Tatsuo KawaiResearcherLegorreta Center for Clinical Transplant Tolerance, Massachusetts General Hospital
Runs the combined kidney and bone-marrow tolerance protocols across HLA barriers and operated on the 2025 engineered-porcine-kidney recipients
- Sana BiotechnologyCompany
Transplanted hypoimmune-engineered primary islet cells into a type 1 diabetes patient with no immunosuppression at all; the cells survived and produced insulin at six and twelve months (2025)
- Immune Tolerance Network ↗Program
NIAID-funded network that has run the clinical tolerance trials in transplantation and autoimmunity for two decades, including the chimerism and withdrawal protocols
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Primate and clinical trials of chimerism and regulatory-cell protocols with drug-withdrawal endpoints and tolerance biomarkers | $$$ $100M – $1B |
| research | Immune-monitoring assays that detect loss of tolerance before graft injury | $$ $10M – $100M |
Depends on
A root node: no prerequisites modeled.